Center of Colorectal and Pelvic Floor Diseases, Aachener Str. 1006-12, 50858, Cologne, Germany.
Competence Network of Chronic Venous Diseases, Kiel, Germany.
Tech Coloproctol. 2017 Apr;21(4):269-276. doi: 10.1007/s10151-017-1599-7. Epub 2017 Mar 7.
There are limited data available concerning endofistular therapies for fistula-in-ano, with our group reporting the first preliminary outcomes of the use of the radial fibre Fistula laser Closing (FiLaC ™) device.
The aim of this study was to assess a cohort of anal fistulae managed with laser ablation plus definitive flap closure of the internal fistula opening over a long-term follow-up. Factors governing primary healing success and secondary healing success (i.e. success after one or two operations) were determined.
The study analysed 117 patients over a median follow-up period of 25.4 months (range 6-60 months) with 13 patients (11.1%) having Crohn's-related fistulae. No incontinence to solid and liquid stool was reported. Minor incontinence to mucus and gas was observed in two cases (1.7%), and a late abscess treated in one case (0.8%). The primary healing rate was 75/117 (64.1%) overall, and 63.5% for cryptoglandular fistulae versus 69.2% for Crohn's fistulae, respectively. Of the 42 patients who failed FiLaC™ 31 underwent a second operation ("Re-FiLaC™", fistulectomy with sphincter reconstruction or fistulotomy). The secondary healing rate, defined as healing of the fistula at the end of the study period, was 103/117 (88.0%) overall and 85.5% for cryptoglandular fistulae versus 92.3% for Crohn's fistulae. A significantly higher primary success rate was observed for intersphincteric-type fistulae with primary and secondary outcome unaffected by age, gender, presence of Crohn's disease, number of prior surgeries and the type of flap designed to close the internal fistula opening.
There is a moderate primary success rate using first-up FiLaC™ treatment. If FiLaC™ fails, secondary success with repeat FiLaC™ or other approaches was high. The minimally invasive FiLaC™ approach may therefore represent a sensible first-line treatment option for anal fistula repair.
肛痿内口治疗的相关数据有限,我们团队报道了首例使用径向纤维肛瘘激光闭合(FiLaC ™)装置的初步结果。
本研究旨在评估一组接受激光消融联合内口切开最终皮瓣闭合的肛瘘患者,随访时间较长。确定了影响一期愈合成功率和二期愈合成功率(即一次或两次手术后的成功率)的因素。
该研究分析了 117 例患者,中位随访时间为 25.4 个月(范围 6-60 个月),其中 13 例(11.1%)为克罗恩相关肛瘘。未报告固体和液体粪便失禁。有 2 例(1.7%)出现少量黏液和气体失禁,1 例(0.8%)出现迟发性脓肿。总体一期愈合率为 75/117(64.1%),其中隐窝型瘘管为 63.5%,克罗恩型瘘管为 69.2%。42 例 FiLaC™ 治疗失败的患者中有 31 例接受了第二次手术(“Re-FiLaC™”,括约肌重建或瘘管切开术)。最终研究期结束时的总二期愈合率为 103/117(88.0%),其中隐窝型瘘管为 85.5%,克罗恩型瘘管为 92.3%。括约肌间型肛瘘的一期成功率显著较高,一期和二期结果不受年龄、性别、克罗恩病、既往手术次数和设计用于闭合内口的皮瓣类型的影响。
首次使用 FiLaC™ 治疗的成功率中等。如果 FiLaC™ 治疗失败,再次使用 FiLaC™ 或其他方法的成功率较高。因此,微创 FiLaC™ 方法可能是肛瘘修复的合理一线治疗选择。